Cancer Treatment Reviews
Volume 31, Supplement 3 , Pages 9-18, 2005

Moving into the future: Treatment of bone metastases and beyond

Department of Breast Medical Oncology, The University of Texas, M.D. Anderson Cancer Center, Houston 77030, USA

Accepted 14 September 2005. published online 24 October 2005.

Summary 

In various common cancers, the skeleton is a preferred site of metastasis. It is also threatened by bone loss resulting from anti-cancer therapy. Like bone metastases in advanced cancer, cancer treatment induced bone loss (CTIBL) substantially increases fracture risk and dramatically decreases quality of life and patient autonomy. Both chemotherapy and endocrine deprivation therapy (EDT) can significantly decrease bone mineral density (BMD). This is aggravated by the often long duration of EDT, particularly in the adjuvant setting. Cumulative bone loss can put patients at risk of osteopenia and osteoporosis. With their known efficacy in preventing skeletal complications in metastatic disease, bisphosphonates (BP) lend themselves to exploring their extended use, notably in preventing CTIBL. Clinical trials have shown BPs to effectively prevent and treat CTIBL, for which they are recommended by ASCO guidelines. Whether BPs also have the potential to prevent metastatic dissemination to bone remains to be determined. Zoledronic acid, a third-generation BP with a favourable efficacy/safety record, was shown by ongoing large clinical trials to not only prevent or reduce CTIBL in early stage cancer, but to actually increase BMD. The current evidence of the potential of zoledronic acid in addressing CTIBL and preventing bone metastases is reviewed.

Keywords: Zoledronic acid, Cancer treatment induced bone loss, Bisphosphonates, Adjuvant therapy, Quality of life, Patient autonomy, Bone, Breast cancer, Prostate cancer, Bone mineral density, Metastases

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0305-7372(05)00162-3

doi:10.1016/j.ctrv.2005.09.003

Cancer Treatment Reviews
Volume 31, Supplement 3 , Pages 9-18, 2005